Bristol Myers Squibb (CELG-RI) Accumulated Expenses (2009 - 2019)

Bristol Myers Squibb has disclosed Accumulated Expenses across 11 years of filings, most recently posting $5.9 billion for Q1 2019.

• In Q1 2019, Accumulated Expenses rose 5.3% year-over-year to $5.9 billion; the TTM figure through Mar 2019 stood at $5.9 billion (up 5.3% YoY), while the FY2018 annual figure was $6.5 billion, up 7.9% from the prior year.
• Accumulated Expenses eased to $5.9 billion in Q1 2019, from $6.5 billion in the prior quarter.
• Over the last five years, Accumulated Expenses for CELG-RI reached as high as $6.5 billion in Q4 2018 and fell as low as $1.8 billion in Q1 2015.
• The 5-year median for Accumulated Expenses is $5.1 billion (2017), against an average of $4.8 billion.
• Annual changes were most pronounced in 2015 — Accumulated Expenses slipped 10.32% — and 2016, when it surged 140.7%.
• A 5-year view of Accumulated Expenses shows it stood at $4.7 billion in 2015, then climbed by 11.25% to $5.3 billion in 2016, then climbed by 14.1% to $6.0 billion in 2017, then gained by 7.9% to $6.5 billion in 2018, then fell by 9.75% to $5.9 billion in 2019.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $5.9 billion, $6.5 billion, and $5.9 billion for Q1 2019, Q4 2018, and Q3 2018 respectively.